HC Wainwright Issues Negative Outlook for ACAD Earnings

Key Points

• HC Wainwright cut its near-term earnings forecast for ACADIA Pharmaceuticals, lowering its Q2 2026 EPS estimate to $0.01 from $0.08. The firm kept a Buy rating and $37 price target despite the more cautious outlook.
• ACADIA’s latest quarterly results missed expectations, with Q1 2026 EPS of $0.02 versus $0.04 expected and revenue of $268.1 million versus $280.25 million expected. Revenue still rose 9.7% year over year, and the company reaffirmed its 2026 guidance.
• Analysts remain broadly positive on the stock overall, with a consensus rating of Moderate Buy and an average price target of $31.00. However, recent estimate cuts suggest some concern about near-term profitability.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2026 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, May 7th. HC Wainwright analyst A. Ghosh now expects that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.08. HC Wainwright currently has a "Buy" rating and a $37.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.42 per share.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 4th. Wolfe Research started coverage on shares of ACADIA Pharmaceuticals in a research report on Monday, February 23rd. They issued an "outperform" rating and a $33.00 target price for the company. Stifel Nicolaus dropped their target price on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a "hold" rating for the company in a research report on Thursday, February 26th. Mizuho raised shares of ACADIA Pharmaceuticals from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $29.00 to $35.00 in a research report on Monday, February 23rd. Finally, Citizens Jmp raised their target price on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $31.00.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $22.40 on Monday. The company has a 50-day moving average price of $22.06 and a 200-day moving average price of $23.90. ACADIA Pharmaceuticals has a 12 month low of $16.76 and a 12 month high of $28.35. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 10.18, a P/E/G ratio of 25.16 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company had revenue of $268.10 million during the quarter, compared to analysts' expectations of $280.25 million. During the same period in the prior year, the business posted $0.11 earnings per share. The company's revenue for the quarter was up 9.7% on a year-over-year basis.

Insider Transactions at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $29,024.28. Following the completion of the transaction, the insider directly owned 29,129 shares of the company's stock, valued at $634,720.91. This trade represents a 4.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the transaction, the executive vice president directly owned 66,145 shares of the company's stock, valued at $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 8,577 shares of company stock valued at $188,426. 26.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 386 shares during the last quarter. Cetera Investment Advisers raised its holdings in ACADIA Pharmaceuticals by 2.7% in the fourth quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company's stock worth $437,000 after buying an additional 436 shares during the last quarter. J.W. Cole Advisors Inc. raised its holdings in ACADIA Pharmaceuticals by 2.5% in the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company's stock worth $551,000 after buying an additional 501 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 4.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 13,192 shares of the biopharmaceutical company's stock worth $352,000 after buying an additional 512 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in ACADIA Pharmaceuticals by 11.2% in the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company's stock worth $114,000 after buying an additional 534 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Neutral Sentiment: ACADIA reported Q1 2026 earnings of $0.02 per share, below the $0.04 consensus, while revenue of $268.1 million also missed estimates. The company did still post 9.7% year-over-year revenue growth and reaffirmed its 2026 guidance. Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
• Neutral Sentiment: HC Wainwright kept a Buy rating and $37 price target, but trimmed several forward EPS estimates for ACADIA, including FY2026 to $0.37 from $0.46 and Q3 2026 to $0.13 from $0.16, reflecting a slightly more cautious outlook. Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (OtherKSPHF), Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
• Neutral Sentiment: The firm also lowered longer-term earnings forecasts for FY2027, FY2028, FY2029 and FY2030, but the reductions were modest and the analyst still sees substantial profit growth over time.
• Negative Sentiment: The latest earnings miss and the analyst estimate cuts likely reinforce concerns that near-term profitability may be more uneven than investors expected, which can weigh on the stock. ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.